World's Best Scientists 2026 revealed!
Michele Milella

Michele Milella

D-Index & Metrics

Medicine

D-Index
76
Citations
30406
World Ranking
18639
National Ranking
754

Michele Milella publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michele Milella sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 657 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michele Milella D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michele Milella sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 76 D-Index — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michele Milella is affiliated with the University of Verona in Italy and has a significant body of research primarily within the field of Medicine. Their research focuses extensively on Oncology, Pulmonary and Respiratory Medicine, and Cancer Research, with additional work in Molecular Biology and Surgery. This body of work covers numerous specialized topics including Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, and Cancer Immunotherapy and Biomarkers.

They have contributed to multiple high-impact journals, frequently publishing in the following venues:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancers
  • Frontiers in Oncology
  • ESMO Open

Their research collaborations include repeated partnerships with a number of co-authors:

  • Sara Pilotto
  • Alice Avancini
  • Ilaria Trestini
  • Lorenzo Belluomini
  • Daniela Tregnago

Examples of recent published articles include:

  • "Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial" (2020, Journal for ImmunoTherapy of Cancer)
  • "Molecular Tumor Boards in Clinical Practice" (2020, Trends in Cancer)
  • "Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study" (2023, The Lancet Oncology)
  • "Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size" (2021, Gut)
  • "Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions" (2021, Cancers)

Their published research addresses key topics such as treatment trials for metastatic cancers, molecular diagnostics in oncology, and biomarker development to predict immunotherapy responses. The work spans clinical trials, molecular tumor board strategies, and genetic characteristics of various cancer types.

In terms of academic output, Michele Milella's contributions have accumulated citations reflecting engagement within the cancer research community, with some papers reaching well over a hundred citations, indicating a sustained influence relevant to clinical oncology and cancer biology.

Best Publications

  • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

    Rafael Rosell;Enric Carcereny;Radj Gervais;Alain Vergnenegre

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • ROLES OF THE RAF/MEK/ERK PATHWAY IN CELL GROWTH, MALIGNANT TRANSFORMATION AND DRUG RESISTANCE

    James A. McCubrey;Linda S. Steelman;William H. Chappell;Stephen L. Abrams

  • Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

    Howard L. Kaufman;Jeffery Russell;Omid Hamid;Shailender Bhatia

  • Patterns of somatic structural variation in human cancer genomes

    Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

  • Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

    Linda S. Steelman;William H. Chappell;Stephen L. Abrams;C. Ruth Kempf

  • Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

    William H. Chappell;Linda S. Steelman;Jacquelyn M. Long;Ruth C. Kempf

  • PTEN: Multiple Functions in Human Malignant Tumors

    Michele Milella;Italia Falcone;Fabiana Conciatori;Ursula Cesta Incani

  • Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia

    L. S. Steelman;S. L. Abrams;J. Whelan;F. E. Bertrand

  • Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia

    Michele Milella;Steven M. Kornblau;Zeev Estrov;Bing Z. Carter

  • Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.

    Donatella Del Bufalo;Ludovica Ciuffreda;Daniela Trisciuoglio;Marianna Desideri

  • Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

    Luisa Carbognin;Sara Pilotto;Michele Milella;Vanja Vaccaro

  • Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mtor cascades which alter therapy response

    James A McCubrey;Linda S Steelman;William H Chappell;Stephen L Abrams

  • FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

    Vaccaro;Sperduti I;Milella M

  • Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

    James Andrew McCubrey;Linda S. Steelman;William H. Chappell;Stephen L. Abrams

  • Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.

    Howard L. Kaufman;Jeffery S. Russell;Omid Hamid;Shailender Bhatia

  • Cytokine-regulated expression of survivin in myeloid leukemia.

    Bing Z. Carter;Michele Milella;Michele Milella;Dario C. Altieri;Dario C. Altieri;Michael Andreeff;Michael Andreeff

  • Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy

    J A McCubrey;L S Steelman;S L Abrams;F E Bertrand

  • Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

    Negin Misaghian;Giovanni Ligresti;L. S. Steelman;Fred E. Bertrand

  • Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials

    Solko W. Schalm;Ola Weiland;Bettina E. Hansen;Michele Milella

Frequent Co-Authors

Francesco Cognetti
Francesco Cognetti Sapienza University of Rome
Aldo Scarpa
Aldo Scarpa University of Verona
Giampaolo Tortora
Giampaolo Tortora University of Verona
Diana Giannarelli
Diana Giannarelli Sapienza University of Rome
James A. McCubrey
James A. McCubrey East Carolina University
Roberto Salvia
Roberto Salvia University of Verona
Daniele Santini
Daniele Santini Università Campus Bio-Medico
Michele Reni
Michele Reni Vita-Salute San Raffaele University
Claudio Bassi
Claudio Bassi University of Verona
Maria Teresa Petrucci
Maria Teresa Petrucci Sapienza University of Rome

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Medicine, several online degrees and career pathways can complement or provide alternatives to traditional medical education in the USA. Online programs offer flexible options for advancing your healthcare career, whether your goal is to manage hospital systems, work in nursing, or specialize further.

A popular pathway is earning a Master of Health Administration from cahme-accredited programs, which focus on health systems leadership and management. Registered Nurses can pursue an rn to bsn online without clinicals to advance their qualifications with minimal time away from their current work.

For nurses seeking higher credentials, online doctorates are increasingly accessible. You can opt for the quickest dnp program to accelerate your career, or explore dnp programs without dissertation for a more practice-focused learning experience.

Online healthcare degrees allow for greater flexibility, empowering students to balance studies with work. Choosing the right program depends on your career goals, desired specialization, and preferred learning style.

Best Scientists Citing Michele Milella

Trending Scientists

Recently Published Articles